EGFR and colorectal carcinoma: (2) Determination of CRIS-D subtype of CRC (with IGF2 overexpression and amplification) for a superior prognostic assessment of CRC patients and the role of IGF2 in desensitization to EGFR blockade in patients with KRAS wt tumors;